Table 4.
Randomized clinical trials of HCC treatment with SA monotherapy
|
Publication |
Type of study |
Number of enrolled patients and controls |
Type of Cancer |
SA used for treatment |
Response to treatment-outcome |
|
|---|---|---|---|---|---|---|
| Patients | Controls | |||||
| Kourumalis 1998
[220] |
RCT |
28* |
30# |
Advanced HCC |
OCT SC (500 μg/d) |
↓AFP,↑S, ↑QoL |
| Yuen 2002
[221] |
RCT |
35* |
35° |
Advanced HCC |
OCT LAR (30 mg/28d) |
None |
| Dimitroulopoulos 2007
[166] |
RCT |
24* (Octreoscan +) |
30° (Octreoscan +) |
Advanced HCC |
OCT LAR (20 to 30 mg/28d) |
↑S, ↑QoL |
| 66# (Octreoscan -) | ||||||
| Becker 2007
[223] |
RCT |
60* |
59° |
Advanced HCC |
OCT LAR (30 mg/28d) |
None |
| Barbare 2009 [224] | RCT | 135* | 137° | Advanced HCC | OCT LAR (30 mg/28d) | =S, ↓QoL |
RCT, Randomized clinical trial.
AFP, Alpha fetoprotein.
S, Survival.
QoL, Quality of life.
*: treated patients.
#: untreated patients.
°: placebo controls.